1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Standard Chemical & Pharmaceutical Co. Ltd.

Standard Chemical & Pharmaceutical Co. Ltd.

TTWSE:1720
57.00
TWD
+0.20
(+0.35%)
6.85EPS
11.28P/E
11.31BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
16.12
16.77
16.9
18.69
19.58
18.18
20.03
21.9
23.42
29.77
31.74
34.54
35.73
35.16
Basic EPS, GAAP
1.58
1.9
1.77
1.73
1.85
1.9
1.92
2.67
3.6
4.15
4.25
4.48
4.72
5.1
Free Cash Flow per Basic Share
0.03
2.05
2.37
0.65
1.64
1.61
2.41
2.9
3.1
0.15
3.6
5.57
6.43
5.9
Dividend per Share
1.08
2.27
0.91
1.36
1.36
1.45
1.36
1.36
1.64
2.27
2.27
2.45
2.55
- -
Book Value per Share
16.74
16.81
18.03
18.92
18.68
18.73
17.22
20.18
22.09
24.18
26.96
30.04
31.16
31.5
Tangible Book Value per Share
15.99
16.07
17.35
18.31
18.08
18.16
16.78
19.72
20.95
23.04
25.87
28.98
30.1
30.47
Basic Weighted Avg Shares
189
197
197
197
197
197
197
197
197
197
197
197
197
201
Sales/Revenue/Turnover
3,054
3,296
3,321
3,674
3,849
3,573
3,937
4,305
4,604
5,851
6,240
6,789
7,023
7,080
Operating Margin (%)
8.68
11.45
11.55
11.38
14.07
11.16
12.95
16.26
19.06
19.42
20.04
20.74
19.37
20.51
Depreciation Expense
141
153
165
192
193
198
229
234
221
299
348
405
434
440
Net Income, GAAP
298
374
348
340
363
374
376
524
707
815
835
881
928
1,027
Effective Tax Rate (%)
17.23
16.32
20.66
19.48
21.24
17.3
19.7
19.07
17.45
17.59
19.47
20.47
17.07
18.13
Profit Margin (%)
9.77
11.36
10.47
9.26
9.44
10.48
9.56
12.17
15.35
13.94
13.38
12.97
13.21
14.51
Working Capital
1,495
1,398
1,426
1,311
1,517
1,611
1,801
1,951
3,068
2,710
3,047
3,341
3,304
3,128
LT Debt
127
181
213
47
187
152
144
202
290
419
445
368
204
200
Total Equity
3,582
3,606
3,887
4,197
4,202
4,246
4,646
4,906
6,800
7,436
8,137
8,976
9,287
9,324
Return on Invested Capital (%)
5.21
7.34
6.76
6.89
8.11
5.84
7.19
9.54
9.68
9.78
10.15
11.01
10.95
11.76
Return on Capital (%)
7.19
8.7
7.46
6.45
5.74
6.07
5.11
7.24
7.93
5.34
5.45
4.85
5.97
6.86
Return on Common Equity (%)
9.71
11.35
10.16
9.37
9.83
10.18
10.11
13.56
17.01
17.93
16.61
15.72
15.42
17.3

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
925
918
837
LT Borrowings
5
- -
- -
LT Finance Leases
199
202
200
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
197
197
197
Market Capitalization
10,525
11,329
11,311

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
5,461
5,483
5,775
Cash, Cash Equivalents & STI
2,385
2,383
2,322
Accounts Receivable, Net
1,085
1,082
1,250
Inventories
1,569
1,598
1,697
Total Current Liabilities
2,157
2,681
2,647
Payables & Accruals
- -
- -
- -
ST Debt
925
918
837
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.53%
14.23%
3.46%
Free Cash Flow
236.96%
444.12%
15.35%
Net Income, GAAP
11.08%
12.68%
5.36%
Sales/Revenue/Turnover
8.07%
10.58%
3.44%
Total Cash Common Dividend
- -
- -
3.7%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,614
1,760
1,742
1,673
6,789
2025
1,640
1,828
1,770
1,785
7,023
2026
1,652
1,873
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.29
1.1
1.11
0.99
4.48
2025
0.99
0.91
1.56
1.17
4.72
2026
1.18
1.2
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
2.45
2025
- -
- -
- -
- -
2.55
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Zi Ting Fan
Full Time Employees
1,805
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 6-20, Tuku Tainan TQ Taiwan 73055
IPO Date
Dec 12, 1995
Website
standard.com.tw
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Standard Chem. & Pharm. Co., Ltd. is a pharmaceutical company based in Tainan City, Taiwan, founded in 1967. The company specializes in the research, development, manufacture, and sale of pharmaceutical products, dietary supplements, and active pharmaceutical ingredients (APIs). Its product portfolio includes finished dosage forms for therapeutic areas such as metabolic, respiratory, musculoskeletal, digestive, circulatory, cardiovascular, nervous systems, anti-infectives, urogenital system, sex hormones, and topical dermatology. The company also produces western medicines, nutritional and functional foods, biochemical nutrition products, and preventive medicines. In addition, Standard Chem. & Pharm. offers medical equipment, animal medicines, cosmetics, and milk powder. It operates as a Contract Manufacturing Organization (CMO) and Contract Development and Manufacturing Organization (CDMO), focusing on innovative drug delivery systems including osmotic-controlled release, micro-encapsulation, pulsatile controlled-release, and lyophilization. Its manufacturing facilities hold approvals from health authorities in the United States, Japan, and Southeast Asian countries. Recent strategic developments include collaboration with major Japanese pharmaceutical companies to expand market presence, and forming strategic alliances with API manufacturers. The company continues to emphasize regulatory compliance and quality assurance aligned with international standards while pursuing innovative technology and superior customer service. These initiatives align with the company’s long-standing corporate philosophy centered on professionalism, excellence, social responsibility, and sustainable growth in the global pharmaceutical industry. Standard Chem. & Pharm. primarily serves domestic and international markets, maintaining a strong reputation for high-quality pharmaceutical solutions.